Prescription drug pricing issues.
Implementation of the Inflation Reduction Act - Public Law No 117-69.
H.R. 485 - the Protecting Health Care for All Patients Act.
Prescription drug pricing issues.
Pricing of Covid 19 vaccines.
H.R. 485 - the Protecting Health Care for All Patients Act.
S. 775 - Increasing Transparency in Generic Drug Applications Act.
S. 1214 - Retaining Access and Restoring Exclusivity Act.
S. 1067 - Ensuring Timely Access to Generics Act.
S. 935 - Fair Accountability and Innovative Research Drug Pricing Act of 2023.
Patent abuse issues.
S. 150 - Affordable Prescriptions for Patients Act of 2023.
S. 79 - Interagency Patent Coordination Act.
Initiatives To Ensure the Robustness and Reliability of Patents Rights (PTO-P-2022-0025).
Joint USPTO-FDA Collaboration Initiatives.
Duration: February 18, 2019
to
December 31, 2023
General Issues: Medicare/Medicaid , Pharmacy , Copyright/Patent/Trademark , Health Issues , Trade (Domestic & Foreign)
Spending: about $580,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: House of Representatives, U.S. Senate, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Patent & Trademark Office (PTO), Executive Office of the President (EOP), White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Rodney Whitlock 2011-2015: Health Policy Director, Sen. Chuck Grassley; 2005-2010: Health Policy Advisor, Senate Finance Committee; 2003-2005: Legislative Director, Rep. Charlie Norwood; 1997-2002: Legislative Assistant, Rep. Charlie Norwood
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2023
McDermott+Consulting LLC terminated an engagement in which they represented Campaign for Sustainable Drug Pricing on Jan. 19.
Original Filing: 301531573.xml
Lobbying Issues
Prescription drug pricing issues.
Implementation of the Inflation Reduction Act - Public Law No 117-69.
H.R. 485 - the Protecting Health Care for All Patients Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Prescription drug pricing issues.
Pricing of Covid 19 vaccines.
H.R. 485 - the Protecting Health Care for All Patients Act.
S. 775 - Increasing Transparency in Generic Drug Applications Act.
S. 1214 - Retaining Access and Restoring Exclusivity Act.
S. 1067 - Ensuring Timely Access to Generics Act.
S. 935 - Fair Accountability and Innovative Research Drug Pricing Act of 2023.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent abuse issues.
S. 150 - Affordable Prescriptions for Patients Act of 2023.
S. 79 - Interagency Patent Coordination Act.
Initiatives To Ensure the Robustness and Reliability of Patents Rights (PTO-P-2022-0025).
Joint USPTO-FDA Collaboration Initiatives.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2023
In Q3, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on Oct. 16, 2023.
Original Filing: 301501180.xml
Lobbying Issues
Prescription drug pricing issues.
Implementation of the Inflation Reduction Act - Public Law No 117-69.
H.R. 485 - the Protecting Health Care for All Patients Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Prescription drug pricing issues.
Pricing of Covid 19 vaccines.
H.R. 485 - the Protecting Health Care for All Patients Act.
S. 775 - Increasing Transparency in Generic Drug Applications Act.
S. 1214 - Retaining Access and Restoring Exclusivity Act.
S. 1067 - Ensuring Timely Access to Generics Act.
S. 935 - Fair Accountability and Innovative Research Drug Pricing Act of 2023.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent abuse issues.
S. 150 - Affordable Prescriptions for Patients Act of 2023.
S. 79 - Interagency Patent Coordination Act.
Initiatives To Ensure the Robustness and Reliability of Patents Rights (PTO-P-2022-0025).
Joint USPTO-FDA Collaboration Initiatives.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2023
In Q2, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on July 19, 2023.
Original Filing: 301483290.xml
Lobbying Issues
Prescription drug pricing issues.
Implementation of the Inflation Reduction Act - Public Law No 117-69.
H.R. 485 - the Protecting Health Care for All Patients Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Prescription drug pricing issues.
Pricing of Covid 19 vaccines.
H.R. 485 - the Protecting Health Care for All Patients Act.
S. 775 - Increasing Transparency in Generic Drug Applications Act.
S. 1214 - Retaining Access and Restoring Exclusivity Act.
S. 1067 - Ensuring Timely Access to Generics Act.
S. 935 - Fair Accountability and Innovative Research Drug Pricing Act of 2023.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent abuse issues.
S. 150 - Affordable Prescriptions for Patients Act of 2023.
S. 79 - Interagency Patent Coordination Act.
Initiatives To Ensure the Robustness and Reliability of Patents Rights (PTO-P-2022-0025).
Joint USPTO-FDA Collaboration Initiatives.
Notice of Public Listening Session and Request for Comment (PTO-P-2022-0037).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2023
In Q1, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on April 20, 2023.
Original Filing: 301466165.xml
Lobbying Issues
Prescription drug pricing issues.
Implementation of the Inflation Reduction Act - Public Law No 117-69.
H.R. 485 - the Protecting Health Care for All Patients Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Prescription drug pricing issues.
Pricing of Covid 19 vaccines.
H.R. 485 - the Protecting Health Care for All Patients Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent abuse issues.
Affordable Prescriptions for Patients Act of 2023.
Interagency Patent Coordination Act.
Initiatives To Ensure the Robustness and Reliability of Patents Rights (PTO-P-2022-0025).
Joint USPTO-FDA Collaboration Initiatives.
Notice of Public Listening Session and Request for Comment (PTO-P-2022-0037).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2022
In Q4, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on Jan. 13, 2023.
Original Filing: 301427185.xml
Lobbying Issues
Issues of prescription drug pricing in Medicare and Medicaid.
Rebate rule.
H.R. 2617- Consolidated Appropriations Act, 2023.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.1391 - Fair Accountability and Innovative Research Drug Pricing Act.
Prescription drug pricing issues.
Patent abuse issues.
Ensuring Innovation Act and the Advancing Education on Biosimilars Act of 2021.
Drug-price Transparency for Competition (DTC) Act.
H.R. 6833 - Affordable Insulin Now Act.
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act.
Implementation of The Inflation Reduction Act (H.R. 5376) Public Law No. 117-169.
H.R. 2617- Consolidated Appropriations Act, 2023.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Stalling Act.
The Affordable Prescriptions for Patients through promoting Competition Act of 2021.
S.4430 - Interagency Patent Coordination and Improvement Act of 2022.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2022
In Q3, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413122.xml
Lobbying Issues
Issues of prescription drug pricing in Medicare and Medicaid.
Rebate rule.
The Inflation Reduction Act (H.R. 5376) Public Law No. 117-169.
H.R. 6833 - Continuing Resolution.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.1391 - Fair Accountability and Innovative Research Drug Pricing Act.
Prescription drug pricing issues.
Patent abuse issues.
Ensuring Innovation Act and the Advancing Education on Biosimilars Act of 2021.
Drug-price Transparency for Competition (DTC) Act.
Prescription Drug User Fee Act.
H.R. 6833 - Affordable Insulin Now Act.
National Coverage Determination on Aduhelm.
User Fee bills.
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act.
The Inflation Reduction Act (H.R. 5376) Public Law No. 117-169.
H.R. 6833 - Continuing Resolution.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Stalling Act.
The Affordable Prescriptions for Patients through promoting Competition Act of 2021.
S.4430 - Interagency Patent Coordination and Improvement Act of 2022.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2022
In Q2, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on July 20, 2022.
Original Filing: 301392808.xml
Lobbying Issues
Issues of prescription drug pricing in Medicare and Medicaid.
Rebate rule.
H.R. 5376 - Build Back Better Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1391 - Fair Accountability and Innovative Research Drug Pricing Act.
Prescription drug pricing issues.
Patent abuse issues.
Ensuring Innovation Act and the Advancing Education on Biosimilars Act of 2021.
Drug-price Transparency for Competition (DTC) Act.
H.R. 5376 - Build Back Better Act.
Prescription Drug User Fee Act.
H.R. 6833 - Affordable Insulin Now Act.
National Coverage Determination on Aduhelm.
User Fee bills.
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Stalling Act.
The Affordable Prescriptions for Patients through promoting Competition Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2022
In Q1, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on April 18, 2022.
Original Filing: 301359643.xml
Lobbying Issues
Issues of prescription drug pricing in Medicare and Medicaid.
Rebate rule.
H.R. 5376 - Build Back Better Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1391 - Fair Accountability and Innovative Research Drug Pricing Act.
Prescription drug pricing issues.
Patent abuse issues.
Ensuring Innovation Act and the Advancing Education on Biosimilars Act of 2021.
Drug-price Transparency for Competition (DTC) Act.
H.R. 5376 - Build Back Better Act.
Prescription Drug User Fee Act.
H.R. 6833 - Affordable Insulin Now Act.
National Coverage Determination on Aduhelm.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Stalling Act.
The Affordable Prescriptions for Patients through promoting Competition Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2021
In Q4, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on Jan. 19, 2022.
Original Filing: 301326471.xml
Lobbying Issues
Issues of prescription drug pricing in Medicare and Medicaid.
Rebate rule.
H.R. 5376 - Build Back Better Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1391 - Fair Accountability and Innovative Research Drug Pricing Act.
Prescription drug pricing issues.
Patent abuse issues.
Ensuring Innovation Act and the Advancing Education on Biosimilars Act of 2021.
Drug-price Transparency for Competition (DTC) Act.
H.R. 5376 - Build Back Better Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Stalling Act.
The Affordable Prescriptions for Patients through promoting Competition Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2021
In Q3, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on Oct. 20, 2021.
Original Filing: 301308314.xml
Lobbying Issues
Issues of prescription drug pricing in Medicare and Medicaid.
Rebate rule.
The Build Back Better Act, a bill to provide for reconciliation pursuant to Title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1391 - Fair Accountability and Innovative Research Drug Pricing Act.
Prescription drug pricing issues.
Patent abuse issues.
Ensuring Innovation Act and the Advancing Education on Biosimilars Act of 2021.
Drug-price Transparency for Competition (DTC) Act.
The Build Back Better Act, a bill to provide for reconciliation pursuant to Title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Stalling Act.
The Affordable Prescriptions for Patients through promoting Competition Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2021
In Q2, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on July 20, 2021.
Original Filing: 301285322.xml
Lobbying Issues
Issues of prescription drug pricing in Medicare and Medicaid.
Rebate rule.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1391 - Fair Accountability and Innovative Research Drug Pricing Act.
Prescription drug pricing issues.
Patent abuse issues.
Ensuring Innovation Act and the Advancing Education on Biosimilars Act of 2021.
Drug-price Transparency for Competition (DTC) Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2021
In Q1, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on April 20, 2021.
Original Filing: 301267610.xml
Lobbying Issues
Issues of prescription drug pricing in Medicare and Medicaid.
Rebate rule.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Prescription drug pricing issues.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on Jan. 20, 2021.
Original Filing: 301238023.xml
Lobbying Issues
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
S. 1895 - Lower Health Care Costs Act
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
H.R. 133 - Consolidated Appropriations Act, 2021
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
Rebate Rule
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1895 - Lower Health Care Costs Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2020
In Q3, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on Oct. 20, 2020.
Original Filing: 301221876.xml
Lobbying Issues
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
S. 1895 - Lower Health Care Costs Act
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act
H.R. 6201 - Families First Coronavirus Response Act
H.R. 748 - Coronavirus Aid, Relief, and Economic Security (CARES) Act
H.R. 6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
Rebate Rule
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1895 - Lower Health Care Costs Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on July 17, 2020.
Original Filing: 301191071.xml
Lobbying Issues
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
S. 1895 - Lower Health Care Costs Act
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act
H.R. 6201 - Families First Coronavirus Response Act
H.R. 748 - Coronavirus Aid, Relief, and Economic Security (CARES) Act
H.R. 6800 - Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1895 - Lower Health Care Costs Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
In Q1, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on April 16, 2020.
Original Filing: 301167753.xml
Lobbying Issues
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
S. 1895 - Lower Health Care Costs Act
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1895 - Lower Health Care Costs Act
H.R. 985 - FAST Generics Act of 2019
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2019
In Q4, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on Jan. 16, 2020.
Original Filing: 301107375.xml
Lobbying Issues
Prescription drug pricing
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions for Patients Act
S. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act
S. 440 - Preserving Access to Cost Effective Drugs Act
S. 340 and H.R. 965 - CREATES Act
S. 1391 and H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 1520 - Purple Book Continuity Act
H.R. 1503 - Orange Book Continuity Act
S. 659 - Biologic Patent Transparency Act
S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act
S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
H.R. 2113 - Prescription Drug STAR Act
S. 617 - Second Look at Drug Patents Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 1865 - Further Consolidated Appropriations Act, 2020
USMCA
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Prescription drug pricing
H.R. 2113 - Prescription Drug STAR Act
S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 1865 - Further Consolidated Appropriations Act, 2020
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Prescription drug pricing
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions for Patients Act
S. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act
S. 440 - Preserving Access to Cost Effective Drugs Act
S. 340 and H.R. 965 - CREATES Act
S. 1391 and H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 1520 - Purple Book Continuity Act
H.R. 1503 - Orange Book Continuity Act
S. 659 - Biologic Patent Transparency Act
S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act
S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
H.R. 2113 - Prescription Drug STAR Act
H.R. 985 - FAST Generics Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent abuse
S. 440 - PACED Act
H.R. 2375 - Preserve Access to Affordable Generics and Biosimilars Act
H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019
S. 617 - Second Look at Drug Patents Act of 2019
S. 1416 - The Affordable Prescriptions for Patients Act
S. 1224 - The Stop STALLING Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2019
In Q3, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on Oct. 11, 2019.
Original Filing: 301064783.xml
Lobbying Issues
Issues relating to prescription drug pricing
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions for Patients Act
S. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act
S. 440 - Preserving Access to Cost Effective Drugs Act
S. 340 and H.R. 965 - CREATES Act
S. 1391 and H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 1520 - Purple Book Continuity Act
H.R. 1503 - Orange Book Continuity Act
S. 659 - Biologic Patent Transparency Act
S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act
S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
H.R. 2113 - Prescription Drug STAR Act
S. 617 - Second Look at Drug Patents Act of 2019
H.R. 3 - Lower Drug Costs Now Act of 2019
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to prescription drug pricing
HHS Rebate Rule
Medicare Part D benefit re-design
H.R. 2113 - Prescription Drug STAR Act
S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act
H.R. 3 - Lower Drug Costs Now Act of 2019
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to prescription drug pricing
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions for Patients Act
S. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act
S. 440 - Preserving Access to Cost Effective Drugs Act
S. 340 and H.R. 965 - CREATES Act
S. 1391 and H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 1520 - Purple Book Continuity Act
H.R. 1503 - Orange Book Continuity Act
S. 659 - Biologic Patent Transparency Act
S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act
S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
H.R. 2113 - Prescription Drug STAR Act
H.R. 985 - FAST Generics Act of 2019
H.R. 3 - Lower Drug Costs Now Act of 2019
S. 2543 - Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent abuse
S. 440 - PACED Act
H.R. 2375 - Preserve Access to Affordable Generics and Biosimilars Act
H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019
S. 617 - Second Look at Drug Patents Act of 2019
S. 1416 - The Affordable Prescriptions for Patients Act
S. 1224 - The Stop STALLING Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2019
In Q2, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $30,000. The report was filed on July 22, 2019.
Original Filing: 301056317.xml
Lobbying Issues
Issues relating to prescription drug pricing
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions for Patients Act
S. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act
S. 440 - Preserving Access to Cost Effective Drugs Act
S. 340 and H.R. 965 - CREATES Act
S. 1391 and H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 1520 - Purple Book Continuity Act
H.R. 1503 - Orange Book Continuity Act
S. 659 - Biologic Patent Transparency Act
S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act
S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
H.R. 2113 - Prescription Drug STAR Act
S. 617 - Second Look at Drug Patents Act of 2019
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to prescription drug pricing
HHS Rebate Rule
Medicare Part D benefit re-design
H.R. 2113 - Prescription Drug STAR Act
S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to prescription drug pricing
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions for Patients Act
S. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act
S. 440 - Preserving Access to Cost Effective Drugs Act
S. 340 and H.R. 965 - CREATES Act
S. 1391 and H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 1520 - Purple Book Continuity Act
H.R. 1503 - Orange Book Continuity Act
S. 659 - Biologic Patent Transparency Act
S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act
S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
H.R. 2113 - Prescription Drug STAR Act
H.R. 985 - FAST Generics Act of 2019
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent abuse
S. 440 - PACED Act
H.R. 2375 - Preserve Access to Affordable Generics and Biosimilars Act
H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019
S. 617 - Second Look at Drug Patents Act of 2019
S. 1416 - The Affordable Prescriptions for Patients Act
S. 1224 - The Stop STALLING Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2019
In Q1, McDermott+Consulting LLC lobbied for Campaign for Sustainable Drug Pricing , earning $10,000. The report was filed on April 10, 2019.
Original Filing: 301023868.xml
Lobbying Issues
Issues relating to prescription drug pricing.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Medicaid
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...